Management of patients during and after exacerbations of chronic obstructive pulmonary disease: the role of primary care physicians

Barbara P Yawn1
Byron Thomashow2

1Department of Research, Olmsted Medical Center, Rochester, MN, USA; 2Division of Pulmonary, Allergy, Critical Care, Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY, USA

Abstract: Current treatments have failed to stem the continuing rise in health care resource use and fatalities associated with exacerbations of chronic obstructive pulmonary disease (COPD). Reduction of severity and prevention of new exacerbations are therefore important in disease management, especially for patients with frequent exacerbations. Acute exacerbation treatment includes short-acting bronchodilators, systemic corticosteroids, and antibiotics if bacterial infections are present. Oxygen and/or ventilatory support may be necessary for life-threatening conditions. Rising health care costs have provided added impetus to find novel therapeutic approaches in the primary care setting to prevent and rapidly treat exacerbations before hospitalization is required. Proactive interventions may include risk reduction measures (eg, smoking cessation and vaccinations) to reduce triggers and supplemental pulmonary rehabilitation to prevent or delay exacerbation recurrence. Long-term treatment strategies should include individualized management, addressing coexisting nonpulmonary conditions, and the use of maintenance pharmacotherapies, eg, long-acting bronchodilators as monotherapy or in combination with inhaled corticosteroids to reduce exacerbations. Self-management plans that help patients recognize their symptoms and promptly access treatments have the potential to prevent exacerbations from reaching the stage that requires hospitalization.

Keywords: COPD, beta-agonists, anticholinergics, self-management plan

Introduction
Exacerbations of chronic obstructive pulmonary disease (COPD) manifest as aggravated respiratory symptoms that can negatively impact a patient’s disease trajectory, often with grim consequences to the individual and society. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines exacerbations as “an event in the natural course of the disease characterized by a change in the patient’s baseline dyspnea, cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset, and may warrant a change in regular medication.” Variations in defining, reporting, or diagnosing episodes may mask the true health and economic burden of exacerbations. Nevertheless, exacerbations are expected to increase in tandem, with projections that deaths from underlying COPD will rise by more than 30% over the next decade without interventions to cut risks. Compounding the societal health impact are the staggering costs involved in treating acute exacerbations, especially if they are severe in nature and therefore warrant hospitalization. The total cost of caring for COPD in the United States is rapidly approaching US$30 billion per year. Most estimates suggest that 70% of that cost relates to treating exacerbations, particularly severe episodes requiring hospitalization and often intensive care.
Exacerbation-prone individuals may be negatively affected in terms of a decreased quality of life, increased hospitalization, and premature deaths, either as a consequence of COPD or coexisting diseases. Exacerbation frequencies and associated hospitalizations in those who are prone to exacerbations typically range from 0.5 to 5.2 exacerbations (depending on definitions used) and from 0.09 to 2.40 hospitalizations per year, respectively. Patients with severe COPD who have frequent exacerbations (≤ 6-month intervals; ≥ three per year) have a more rapid decline in lung function and worse health-related quality of life than those who experience infrequent exacerbations. However, data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) initiative suggest that there is a frequent-exacerbation phenotype that is independent of disease severity. Exacerbation duration is variable but may last up to 5 weeks, and the impact can be prolonged or permanent; there is also a high risk of a recurring exacerbation in the 8-week period following an index event. The devastating consequences of exacerbations are underscored by high rates of relapse (22%-32% of emergency department patients visit the department again), 1-year (25%) and 5-year (44%) hospital readmissions, and overall treatment failures (32%), as well as high exacerbation-related fatalities (2.5%-10.0%), increasing in intensive care unit patients to 20%-24%.

Reports are beginning to illuminate the gap between guideline-recommended and actual treatment and follow-up care of hospitalized COPD patients. One retrospective analysis of these patients showed that prescribed respiratory drugs were underused, overused, or misused. A separate retrospective cohort study showed that hospitalized patients with acute exacerbations received adequate care, but that there were opportunities to improve treatment in both the inpatient and outpatient settings. Recognition of the cost-prohibitive nature and frequent treatment of recurrent exacerbations in hospitals has added to the interest in treating milder or frequent episodes in the primary care setting. Ultimately we will need to balance the cost of potential preventive therapies versus the benefit of preventing exacerbations. The aim of this review is to describe strategies that may improve the prevention and treatment of exacerbations.

**Triggers and effects of COPD exacerbations**

The transition from stable-state COPD to onset of an exacerbation typically involves amplified airway inflammation. Infections of the tracheobronchial tree (viral and bacterial), exposure to air pollution (eg, inhalation of tobacco smoke, occupational and environmental exposure to particulates or noxious gases), and suboptimal treatment adherence account for most identifiable causes of exacerbations. Many exacerbations triggered by respiratory viral mono- or coinfections are more likely to be severe, prolonged, and associated with hospital admissions compared with episodes where respiratory viruses were not detected. Further investigation is needed to establish whether chronic respiratory viral infection of stable COPD patients’ Airways predisposes patients to exacerbations. Many exacerbations are triggered by a bacterial infection caused by, for example, *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Pseudomonas aeruginosa*. Elevated levels of the latter pathogen are more likely to be associated with severe COPD or when systemic steroids and/or antibiotics had been prescribed in the preceding months. In addition, *Bordetella pertussis*, the re-emergent pathogen responsible for pertussis (whooping cough), has been associated with 31% of acute exacerbations of chronic bronchitis, according to one pilot study. While infections are the most common cause of exacerbations, the apparent increased susceptibility to this etiologic factor in patients with COPD is not well understood. Recent evidence suggests that an altered airway epithelial cell phenotype may contribute to increased susceptibility to viral infection in patients with COPD compared with control subjects.

Exacerbations may also increase the risk of nonpulmonary events and related mortality. Specific molecular pathways culminating in exacerbations remain to be elucidated, but elevated systemic inflammatory markers are often present during acute exacerbations and have been associated with a small but statistically significant risk of stroke and cardiovascular events. Worsening bronchoconstriction from an exacerbation may elevate pulmonary artery pressures, placing an increased burden on the right side of the heart. A higher post-exacerbation myocardial infarction incidence has been reported in patients with more frequent exacerbations, although the reasons for this finding remain unclear. The recent ECLIPSE study showed that more frequent exacerbations were also associated with greater impairment in health status.

Patients who have frequent exacerbations have been defined as having more than the annual median number of episodes for a given study, usually two steroid- and/or antibiotic-requiring or three symptom-defined exacerbations. These patients can exhibit elevations in specific blood and airway-derived biomarkers compared with those who have infrequent exacerbations, generally have a faster decline
Diagnosis of an exacerbation

Diagnosis and staging of COPD exacerbations depend on symptom-based criteria and/or health care resource utilization (Table 1). Since increasing confusion may be part of respiratory compromise, it may also be beneficial to assess a patient's mental status during evaluation (Table 2). Of the known hospitalization indicators, escalating respiratory distress, onset of respiratory acidosis, significant nonpulmonary conditions, and the need for ventilatory (invasive or noninvasive mechanical) support are especially important, since they are associated with an increased risk of death.1

While a severe exacerbation is almost always identified and treatment provided, many milder events go unreported by patients29 or are labeled by clinicians as upper respiratory tract infections or acute bronchitis. Recognizing and appropriately treating all exacerbations, including milder symptom worsening reported by patients, may help prevent future exacerbations. Composite indices can help identify patients at increased risk of developing a future exacerbation. Examples include indices for (1) BODE (body mass index, airflow obstruction [forced expiratory volume in 1 second (FEV1)], dyspnea, and exercise capacity)30 and (2) DOSE (dyspnea scale, airflow obstruction [FEV1], smoking status [current versus former], and prior exacerbation frequency).31 In addition, the Exacerbations of Chronic Pulmonary Disease Tool, a Patient-Reported Outcome measure initiative, has been designed to standardize evaluations of the frequency, severity, and duration of acute exacerbations of COPD and chronic bronchitis. A recent observational study suggests that this 14-item digital diary is reliable, valid, and sensitive to change with exacerbation recovery.32

Since no single test can fulfill all requirements, additional evaluations are needed to accurately identify exacerbation-prone patients. Inadequate recording of relevant factors (medical history, risk factors, exercise tolerance), lack of equipment, clinicians with limited training, as well as patients with multiple chronic conditions may further complicate diagnosis.

Investigational biomarkers associated with exacerbation etiology, severity, and recovery can potentially augment the current diagnostic toolkit. One example is the hormone precursor procalcitonin, which is elevated in serum when bacterial infections are present.33 Ongoing studies are needed to assess the routine use of procalcitonin to diagnose these exacerbations (in order to reduce patient exposure to antibiotics); its use has not yet been recommended by guidelines. Further studies are also needed to assess the value of routine testing for biomarkers found in association with exacerbations, such as fractional exhaled nitric oxide and C-reactive protein (CRP).33–35

Table 1 Commonly used definitions of exacerbation severity33,34

<table>
<thead>
<tr>
<th>Degree of exacerbation (number of symptomsa)</th>
<th>Feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild (1 of 3 present)</td>
<td>Symptoms can be controlled by increasing prescribed medication dose</td>
</tr>
<tr>
<td>Moderate (2 of 3 present)</td>
<td>Symptoms require corticosteroids and/or antibiotics</td>
</tr>
<tr>
<td>Severe (all 3 present)</td>
<td>Symptoms need evaluation in a hospital/ED/intensive care unit</td>
</tr>
</tbody>
</table>

Notes: aBeyond periodic variability necessitating a change in medical management; bTreatment in a primary care setting is sufficient for patients with few comorbidities.

Abbreviation: ED, emergency department.

Treatment of acute exacerbations

Given the frequently fatal nature of COPD exacerbations, they must be recognized early and accurately to allow prompt initiation of therapy. Early detection and treatment of exacerbations can improve patients' wellbeing and health-related quality of life and reduce hospitalizations.1 The recommended treatment algorithm for exacerbations is delineated in Figure 1.1,36,37 Pharmacotherapy is intended to relieve dyspnea, reduce airway inflammation, improve lung function, and eradicate infections, potentially moderating disease progression. A reliable predictor of a recurrent exacerbation is a history of previous exacerbations.6,9

Bronchodilators

The first step in the treatment of an exacerbation is to increase the dose of inhaled bronchodilator to decrease dyspnea.1 Short-acting β-agonists (SABAs) are used as needed because they have a rapid onset of action on bronchoconstriction. Prescriptions of these bronchodilators are subject to consideration of known adverse events for SABAs (eg, hypokalemia).1 Combining SABAs with inhaled short-acting anticholinergics (SAACs) may have additional benefit. Common side effects of anticholinergics include dry mouth and
Table 2 Hospitalization indicators and evaluations of exacerbations

<table>
<thead>
<tr>
<th>General indications for hospitalization</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Frequent episodes</td>
</tr>
<tr>
<td>• Diagnostic uncertainty</td>
</tr>
<tr>
<td>• Advanced age</td>
</tr>
<tr>
<td>• Change in mental status</td>
</tr>
<tr>
<td>• Symptoms that are poorly responsive to current treatment</td>
</tr>
<tr>
<td>• Advanced COPD(^\text{1})</td>
</tr>
<tr>
<td>• Little or no psychosocial support</td>
</tr>
<tr>
<td>• Intensive care is warranted for life-threatening episodes associated with: respiratory failure; shock; hemodynamic instability; hypoxic renal, hepatic, or brain dysfunction</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symptomatic indications and diagnostic tests</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>• Exposure to risk factors (genetic predisposition; inhalation of tobacco smoke or environmental pollutants) and/or low exercise tolerance</td>
</tr>
<tr>
<td>• Intensified respiratory symptoms (cough, sputum production, and dyspnea)</td>
</tr>
<tr>
<td>• Lethargy, fever, fatigue</td>
</tr>
<tr>
<td>• Change in sputum volume and appearance</td>
</tr>
<tr>
<td>• Signs of respiratory failure(^c)</td>
</tr>
<tr>
<td>• Sa(_\text{O}_2) &lt; 92%</td>
</tr>
<tr>
<td>• Chest discomfort</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>• Metabolic disorder</td>
</tr>
<tr>
<td>• Current smokers</td>
</tr>
<tr>
<td>• Underutilization or poor response to long-term oxygen treatment.</td>
</tr>
</tbody>
</table>

Notes: \(^{1}\)FEV\(_1\)/FVC < 70%; FEV\(_1\) < 50% with respiratory symptoms either at rest or upon minimal exertion; \(^{2}\)Indications with or without a prior COPD diagnosis may warrant several evaluations. There could potentially be a reciprocal and causal relationship between COPD and nonpulmonary conditions. Examples of the latter conditions include cardiovascular diseases, stroke, pneumonia, sepsis, diabetes mellitus, and renal or hepatic failure; \(^{3}\)PaO\(_2\) < 8.0 kPa with or without PaCO\(_2\). 
Abbreviations: ABG, arterial blood gas; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; FEV\(_1\), forced expiratory volume in 1 second; FVC, forced vital capacity; Pa, partial pressure; Sa, saturation.
Management of patients during and after exacerbations of COPD

Constipation.

If patients are already receiving maintenance pharmacotherapies, some caution needs to be exercised when adding regular doses of SABAs or SAACs, since side effects could increase. Methylxanthine derivatives may play a role as second-line therapies in selected cases where patients are poorly responsive to SABAs or SAACs; however, their significant potential side effects when used in high doses or combined with other common chronic disease therapies warrant close clinical and biochemical monitoring for possible adverse events.

Corticosteroids

The major use for systemic steroids is in combination with other therapies, eg, bronchodilators, during an acute exacerbation. No steroid taper is required for a short course of systemic steroid therapy, per GOLD guidelines. Recent data suggest that oral corticosteroids are as effective as intravenous corticosteroids in patients hospitalized with exacerbations; however, prolonged treatment with oral corticosteroids (>10 days) does not result in greater efficacy and increases the risk of side effects such as hyperglycemia and muscle atrophy. While an approved inhaled corticosteroid (ICS)/long-acting β-agonist (LABA) combination is used in the context of preventing the next exacerbation, the GOLD guidelines state that the ICS, budesonide, “alone, or in combination with formoterol may be an alternative (although more expensive) to oral glucocorticosteroids in the treatment of exacerbations.”

Antibiotics

Bacterially triggered exacerbations are usually amenable to appropriate antibiotic therapy. Current antibiotic recommendations (Table 3) will depend on the bacterial strains that are responsive or resistant to antimicrobial therapies. Relevant factors that may guide specific antibiotic choices are drug

---

**Figure 1** Treatment algorithm for patients with exacerbations.
Adapted from the Global Initiative for Chronic Obstructive Lung Disease guidelines, Anthonisen et al, and Celli et al.

Abbreviation: COPD, chronic obstructive pulmonary disease.
penetration into pulmonary airways, efficacy of microbial clearance, treatment duration, likelihood of pathogen recurrence, and any drug-related adverse events.39

Adding antibiotics to corticosteroid therapy has been shown to prolong the time to the next exacerbation and to reduce the risk of a new exacerbation versus corticosteroid use alone.40 One meta-analysis showed that treatment duration (≤ 5 days) did not affect the cure rates attributed to broad-spectrum antibiotics,41 whereas another meta-analysis showed a lower risk of treatment failure for broad-spectrum versus narrow-spectrum antibiotics.42 A randomized trial of a broad spectrum antibiotic, doxycycline, added to systemic corticosteroids in selected patients hospitalized with acute exacerbations of COPD (AECOPD), demonstrated similar clinical success on day 30 in intent-to-treat (odds ratio 1.3, 95% confidence interval [CI] 0.8–2.0) and per-protocol patients, but on day 10 those receiving doxycycline demonstrated improvement in symptom score, microbiologic outcome, and clinical cure.43 In this study, patients with higher CRP levels treated with antibiotics had a better response than those in the placebo group, suggesting a potential future importance for this biomarker in defining therapeutic paths.

Oxygen and noninvasive ventilation
Oxygen requirements typically increase during exacerbations. Oxygen supplementation and/or ventilation should be considered for patients who are experiencing signs of respiratory failure (eg, worsening hypercapnia, hypoxemia, acidosis, or pulmonary embolism) or have coexisting conditions such as myocardial infarction or sepsis.44 Long-term oxygen therapy (indicated if saturation level is below 88%) can correct hypoxemia in patients with very severe COPD and improve overall health status.1 If the patient is discharged from the hospital on oxygen or on higher amounts of oxygen than on admission, the oxygen requirement must be reevaluated as the patient improves, in order to better define long-term requirements.

If patients with severe exacerbations are poorly responsive to oxygen supplementation alone, they may

Table 3 Antibiotic treatment in exacerbation of COPD

<table>
<thead>
<tr>
<th>COPD exacerbation indication</th>
<th>Oral treatment</th>
<th>Alternative oral treatment</th>
<th>Parenteral treatment</th>
</tr>
</thead>
</table>
| Group A (mild exacerbation: no risk factors for poor outcome) | Patients with only one cardinal symptom should not receive antibiotics if indication then:  
• β-lactam (penicillin, ampicillin/amoxicillin)  
• Tetracycline  
• Trimethoprim/sulfamethoxazole | β-lactam/β-lactamase inhibitor (co-amoxiclav)  
• Macrolides (azithromycin, clarithromycin, roxithromycin)  
• Cephalosporins – second or third generation  
• Ketolides (telithromycin) | β-lactam/β-lactamase inhibitor (co-amoxiclav)  
• Macrolides (azithromycin, clarithromycin, roxithromycin)  
• Cephalosporins (second or third generation)  
• Fluoroquinolones (levofloxacin, moxifloxacin) |
| Group B (moderate exacerbation with risk factor(s) for poor outcome) | • β-lactam/β-lactamase inhibitor (co-amoxiclav) | Fluoroquinolones (gemifloxacin, levofloxacin, moxifloxacin) | β-lactam/β-lactamase inhibitor (co-amoxiclav, ampicillin/sublactam)  
• Cephalosporins (second or third generation)  
• Fluoroquinolones (levofloxacin, moxifloxacin)  
• β-lactam with P. aeruginosa activity |
| Group C (severe exacerbation with risk factors for Pseudomonas aeruginosa infection) | In patients at risk for Pseudomonas infections:  
• Fluoroquinolones (ciprofloxacin, levofloxacin – high dose) | Fluoroquinolones (ciprofloxacin, levofloxacin – high dose) | Fluoroquinolones (ciprofloxacin, levofloxacin – high dose)  
• β-lactam with P. aeruginosa activity |

Notes: Relevant risk factors: presence of comorbid diseases, severe COPD, frequent exacerbations (>3/year), and antimicrobial use in the last 3 months.  
All patients with symptoms of a COPD exacerbation should be treated with additional bronchodilators ± glucocorticosteroids;  
Classes of antibiotics are provided (with specific agents in parentheses);  
No particular order.  
Cardinal symptoms are increased: dyspnea, sputum volume, and sputum purulence;  
This antibiotic is not appropriate in areas where there is increased prevalence of β-lactamase producing Haemophilus influenzae and Moraxella catarrhalis and/or of Streptococcus pneumoniae resistant to penicillin;  
Not available in all areas of the world;  

Abbreviation: COPD, chronic obstructive pulmonary disease.
be candidates for ventilatory support to avoid intubation, including noninvasive ventilation (NIV) in the case of eligible individuals.\(^1\) Although the prognosis is poor for all patients requiring ventilatory support, evidence based on data from a subset of patients suggests that NIV reduces morbidity and mortality rates and intensive care unit or hospital lengths of stay.\(^{45}\)

**Reduction/prevention of exacerbations**

Although patients hospitalized with severe exacerbations usually receive recommended care, most patients are not discharged with appropriate support and medications.\(^{19}\) It is debatable whether health care insurance will continue to pay for potentially avoidable COPD-related hospital readmissions. Thus, there is a growing impetus to prevent or reduce exacerbation severity in the primary care outpatient setting to avoid hospitalization. Patients with exacerbations may benefit from risk reduction measures and maintenance pharmacotherapies, supplemented with self-management plans, as part of pulmonary rehabilitation (PR).

**Risk reduction**

Results from a large-scale retrospective analysis of current and former smokers showed that smoking cessation significantly reduced exacerbations after adjusting for age, comorbidities, disease severity, and socioeconomic status (adjusted hazard ratio [HR] 0.78, 95% CI 0.75–0.87).\(^{46}\) These data support guideline recommendations for smoking cessation as a risk reduction measure regardless of disease status.\(^1\)

Seasonal influenza and pneumococcal pneumonia vaccinations should be standard, as appropriate for COPD patients, according to the GOLD guidelines.\(^1\) Elderly COPD patients (aged ≥ 65 years), in particular, suffer significant adverse events from influenza and derive health benefits from vaccinations in the form of fewer hospitalizations, outpatient visits, and fatalities. Immunizations in this high-risk group should, therefore, be a priority for all clinicians.\(^{47}\) Consideration should also be given to providing a one-time dose of the tetanus-diphtheria-acellular-pertussis (Tdap) vaccine to previously unvaccinated individuals with COPD (aged < 65 years), based on medical and other indications;\(^{48}\) for example, in the face of a pertussis epidemic in local children. The Advisory Committee on Immunization Practices recommends Tdap for older individuals (aged ≥ 65 years) not previously immunized with this vaccine who anticipate close contact to infants (aged < 12 months).\(^{49,49}\)

Antibiotic prophylaxis with a low-dose macrolide has emerged as another possible therapeutic option for reducing exacerbation frequency. In a 12-month study of COPD patients experiencing moderate and/or severe exacerbations (35% experienced three or more exacerbations in the year before recruitment), twice-daily administration of erythromycin, was associated with a significant reduction in exacerbations compared with placebo.\(^{50}\) Results from a prospective, randomized, double-blind, placebo-controlled trial showed that long-term, once-daily administration of azithromycin, in addition to usual care, decreased the frequency of AECOPD (1.47 versus 1.84/patient-year, \(P = 0.004\)) and improved the quality of life of exacerbation-prone COPD patients.\(^{51}\)

**Maintenance pharmacotherapies**

Results from two megatrials, Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT\(^{\text{TM}}\))\(^{52}\) and Towards a Revolution in COPD Health (TORCH),\(^{53}\) have shown a benefit for a long-acting anticholinergic (LAAC), tiotropium, and a LABA/ICS combination (salmeterol/fluticasone) in reducing key clinical endpoints, including exacerbations. The United States Food and Drug Administration (FDA) has approved tiotropium to reduce exacerbations in COPD patients and salmeterol/fluticasone to reduce exacerbations in COPD patients with a history of exacerbations. In the UPLIFT trial, median time to the first exacerbation was 16.7 months (95% CI 14.9–17.9) in the tiotropium group versus 12.5 months (95% CI 11.5–13.8) in the placebo group (HR 0.86, 95% CI 0.81–0.91). Tiotropium treatment was also associated with a 14% decrease in the mean number of exacerbations versus placebo (\(P < 0.001\)).\(^{52}\)

A study by Niewoehner et al showed tiotropium reduced the proportion of patients with moderate to severe COPD experiencing exacerbations and may reduce health care utilization compared with placebo.\(^{54}\) In this study, the treatment groups received “usual care” as well as study treatment that could include respiratory medications other than anticholinergic bronchodilators, which may reflect “real-world” practice.\(^{54}\) In the 3-year TORCH study, salmeterol/fluticasone (50 µg/500 µg) treatment versus placebo resulted in a rate ratio for exacerbations of 0.75 (95% CI 0.69–0.81; \(P < 0.001\)), which is a reduction of 25% in affected individuals.\(^{55}\) Another 1-year study showed that treatment with salmeterol/fluticasone (50 µg/250 µg) reduced exacerbation rates in patients with moderate to severe COPD by 30.5% compared with salmeterol.\(^{55}\) A direct comparison of tiotropium (18 µg) and salmeterol/fluticasone...
(50 μg/500 μg) in patients with severe to very severe COPD showed no statistical difference in exacerbation rates over 2 years. However, tiotropium (18 μg) was more effective than salmeterol (50 μg) in all assessed exacerbation endpoints and across all the major subgroups, according to a separate 1-year comparative study of only the LAAC and LABA given to patients with moderate to severe COPD and a history of exacerbations.

Another LABA/ICS combination, budesonide/formoterol (not FDA-indicated for COPD exacerbations), administered to patients with moderate to severe COPD, reduced systemic steroid-requireing exacerbations versus formoterol alone in a 6-month study (20%–25% exacerbation reductions with budesonide-containing treatments versus formoterol or placebo alone). Similarly, a 1-year study of the treatment effects of these agents showed 25%–29% lowered exacerbation rates (with budesonide-containing therapies) beyond reductions achieved with formoterol alone. In addition, budesonide/formoterol plus tiotropium specifically reduced the number of exacerbations by 62% versus tiotropium treatment alone.

Roflumilast, an oral phosphodiesterase-4 inhibitor, is indicated in the United States as a treatment to reduce exacerbations by 62% versus tiotropium treatment alone. Roflumilast resulted in reduced health care utilization and costs in a separate United States study. Since this is, in essence, a behavioral intervention, durable health benefits can be reaped only if a patient can sustain behavior and lifestyle changes over the long term.

### Pulmonary rehabilitation

PR as an adjunctive therapy can improve dyspnea, exercise tolerance, and health-related quality of life, as well as reduce recurrent exacerbations and, hence, the risk of hospitalization in some patients. Stage-appropriate PR should include one or more aspects of disease and inhaler education, optimization of daily living activities, self-management of symptoms, anxiety and stress control, oxygen therapy, guidance for early detection and treatment of COPD exacerbations, smoking cessation, nutrition, structured exercise, and increased physical activity at home. A systematic review has shown that PR has the potential to reduce the number of exacerbations and associated hospital visits as well as their severity. In a multicenter study, tiotropium plus PR-treated patients experienced fewer exacerbations and exacerbation days, and improvements in health-related quality of life, relative to the tiotropium-only group. Clinically meaningful changes in exercise tolerance, dyspnea, and fatigue were observed in United Kingdom patients treated for exacerbations in a hospital setting and enrolled 10 days post discharge in an 8-week PR program (10% of rehabilitated patients versus 42% of usual-care patients; \(P = 0.01\)). Shuttle-walk distance was nearly doubled in rehabilitated patients, and dyspnea and fatigue were significantly reduced.

Beginning PR after resolution of an acute exacerbation resulted in reduced health care utilization and costs in a separate United States study. Since this is, in essence, a behavioral intervention, durable health benefits can be reaped only if a patient can sustain behavior and lifestyle changes over the long term.

### Cardiac protective therapies

Cardiovascular events are extremely common in COPD patients and impact morbidity and mortality. These diseases cause 25% of deaths and nearly 50% of hospitalizations in patients with mild to moderate COPD, as well as significantly increasing the duration of hospitalization and risk of premature death in patients with severe exacerbations. It has also been suggested that all patients who have frequent exacerbations may need treatments to reduce cardiovascular events during stable disease periods.

European guidelines state that COPD is not a contraindication for evidence-based cardiovascular disease treatment with...
β-blockers; however, their underuse in COPD has classically been associated with concern over the risk of worsening bronchospasm. Emerging evidence suggests that treatment with cardioselective β-blockers is safe, well tolerated, and reduces the risk of exacerbations and premature deaths in COPD patients with coexisting cardiovascular disease. In the absence of larger prospective randomized clinical trials, the decision to use β-blockers in COPD patients must be made very carefully. However, the concept that bronchodilators (eg, β-agonists) and β-blockers could both decrease exacerbations further emphasizes the complexity of these events.

Self-management

Self-management plans empower patients with a history of exacerbations by teaching problem-solving skills, including recognition and interpretation of symptom changes, and next steps (eg, seeking access to appropriate care). Patient education is a vital aspect of guided self-management in order to address some of the issues underlying suboptimal medication adherence, such as compromised inhaler technique (as described in detail elsewhere). Written action plans are also important components of self-management and could be part of PR or an existing chronic care program. One example currently being evaluated by the Canadian Thoracic Society provides patients with advice on self- or medical-care visits, as appropriate. Analyses of the benefits of action plans have produced variable results, mainly because of the heterogeneity in plans, study populations, follow-up time, and outcome measures, although two separate analyses showed that self-management plans increased appropriate treatment and reduced exacerbation recovery time. Where feasible, a 24-hour telephone support service may reduce the number of hospitalizations. Other forms of support can be considered to supplement self-management plans (eg, Web-based consultation services or videophones); however, this type of home monitoring may be expensive to set up, and many older patients may not be able to master the technology. While self-management plans are very important, their benefits have yet to be evaluated in patients immediately following hospitalization or in those who are prone to frequent exacerbations.

Lung volume reduction surgery

Lung volume reduction surgery has been shown to improve the quality of life, exercise capacity, and survival in a carefully selected group of patients with upper-lobe predominant emphysema. The evidence suggests that patients who meet pre-specified criteria for surgery and undergo the procedure may receive an additional benefit in terms of a reduction in exacerbations, potentially by improving respiratory mechanics and decreasing the volume of trapped air from hyperinflated regions of the lungs.

Summary

Many patients with COPD delay reporting exacerbations, which leads to detrimental consequences to their quality of life. Severe exacerbations, usually involving hospitalization, are associated with enormous health and socioeconomic costs. Short-acting bronchodilators and oxygen are prescribed to relieve dyspnea, corticosteroids to decrease inflammation during an acute exacerbation, and appropriate antibiotic therapy to treat bacterial infections. A long-term treatment plan should include one or more available classes of drugs (LAAC, LABA [alone or in combination], an ICS/LABA combination, and phosphodiesterase-4 inhibitor) that represent maintenance pharmacotherapies to prevent future exacerbations, as well as management of coexisting nonpulmonary conditions and strategies to optimize adherence to inhaled medications. Supplementary PR may be important in preventing or delaying the recurrence of exacerbations in some patients after they have recovered from an acute event. Self-management plans, as part of PR or a chronic care program, may contribute to a reduction in the frequency and severity of exacerbations.

Conclusion

Exacerbations affect patient longevity and quality of life, thereby dramatically contributing to the cost of care for affected individuals. By helping to prevent, recognize, and appropriately treat these events, clinicians can have a major impact on the course of COPD.

Acknowledgments

Manuscript preparation, including medical writing assistance, which was provided by Zeena Nackerdien, PhD, of Envision Scientific Solutions, was supported by Boehringer Ingelheim Pharmaceuticals, Inc and Pfizer Inc. The article reflects the concepts of the authors and is their sole responsibility. It was not reviewed by Boehringer Ingelheim Pharmaceuticals, Inc and Pfizer Inc, except to ensure medical and safety accuracy.

Disclosure

Dr Yawn participated in COPD studies from Boehringer Ingelheim, Novartis, and GlaxoSmithKline, for which
References


